Dianthus Therapeutics Updates Pipeline with Promising Data

Dianthus Therapeutics recently announced its second-quarter 2026 financial results, accompanied by substantial updates across its entire drug pipeline. The company is actively pursuing three distinct autoimmune disease treatment strategies simultaneously.

Significant progress was reported from the CAPTIVATE Phase 3 trial of claseprubart for chronic inflammatory demyelinating polyneuropathy. An interim analysis of 40 participants in Part A revealed a 75% response rate, surpassing the company's target. Claseprubart demonstrated a good safety profile, with no serious related infections or adverse events reported to date. Guidance for Part B is anticipated by the end of 2026.

Furthermore, the Phase 2 MoMeNtum trial for multifocal motor neuropathy has completed enrollment with 46 participants, exceeding its goal. Top-line results are expected in December. Dianthus also commenced its Phase 3 EMERGE trial for generalized myasthenia gravis in June, investigating two subcutaneous dosing schedules. The FDA has accepted revised trial protocols, removing certain screening requirements and classifying potential lupus risk as reversible.

As of June 30, Dianthus Therapeutics held approximately $1.2 billion in cash, sufficient to cover operations through 2030. The company also plans to initiate Phase 1 trials for DNTH312, a novel fusion protein, by the end of 2027.

This extensive clinical activity has led to increased operating expenses. Research and development costs rose to $48.7 million in the quarter, driven by higher clinical trial expenses and expanded headcount. General and administrative costs also increased to $13.6 million. Consequently, the net loss for the quarter widened to $50.2 million, though the per-share loss remained stable at $0.90.